GLP-1 Semaglutide in Pennsylvania: Buy Online for $99/Month
Pennsylvania residents from Philadelphia to Pittsburgh can access affordable semaglutide through licensed telehealth.
Pennsylvania faces significant obesity challenges, with approximately 34% of adults classified as obese. Brand-name semaglutide costs over $1,000/month, but TRIMI offers compounded semaglutide for just $99/month -- accessible to all Pennsylvanians through licensed telehealth.
Pennsylvania GLP-1 Access
The Pennsylvania State Board of Pharmacy regulates compounding operations statewide. Pennsylvania's telehealth laws allow licensed providers to prescribe GLP-1 medications after virtual consultations.
Pennsylvania at a Glance
- • Population: ~13 million residents
- • Obesity rate: ~34% of adults
- • Telehealth: Supported for GLP-1 prescriptions
- • Compounding: Regulated by PA Board of Pharmacy
- • Shipping: 3-5 day delivery statewide
Cost Comparison
| Option | Monthly | Insurance |
|---|---|---|
| Wegovy (brand) | $1,000-$1,400 | Recommended |
| TRIMI | $99/month | No |
Regional Access
- Philadelphia metro: Skip Center City clinic waits with telehealth
- Pittsburgh: Steel City residents get convenient virtual access
- Allentown/Lehigh Valley: Growing metro with full coverage
- Central PA (Harrisburg, State College): Equal access statewide
- Rural PA: Appalachian and rural communities fully served
How to Get Started
Consultation
Online assessment with PA-licensed provider.
Evaluation
BMI, health history, and personalized plan.
$99/Month
No insurance, no prior auth, no surprises.
Delivery
3-5 business day delivery to any PA address.
Medical Disclaimer
Informational only. Semaglutide requires provider evaluation. Side effects: nausea, vomiting, diarrhea, constipation. Not for MTC/MEN 2 history.
Start Semaglutide in Pennsylvania
Affordable GLP-1 for all PA residents. $99/month with statewide shipping.
Get Started for $99/MonthMore on state guides
Sources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).